Compounds > 3-nitro-n-(4-phenoxyphenyl)benzamide
Page last updated: 2024-11-09

3-nitro-n-(4-phenoxyphenyl)benzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID715924
CHEMBL ID4575751
MeSH IDM0579595

Synonyms (22)

Synonym
OPREA1_425613
OPREA1_777421
3-nitro-n-(4-phenoxyphenyl)benzamide ,
AKOS001414914
F1107-0308
316146-57-3
ica-105574
STL377841
ica105574
gtpl7656
ica 105574
3-nitro-n-[4-(phenoxy)phenyl]benzamide
DTXSID80351981
ica-105574, >=98% (hplc)
Q27078021
EX-A4991
3-nitro-n-[4-phenoxyphenyl]-benzamide
CHEMBL4575751
HY-124702
CS-0087358
AC-36972
Z28286052
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346732Human Kv10.1 (Voltage-gated potassium channels)2013Molecular pharmacology, Apr, Volume: 83, Issue:4
ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)2010Molecular pharmacology, Jan, Volume: 77, Issue:1
Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.24 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		2.0710benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
clofilium
clofilium: RN given refers to parent cpd; structure		2.0710benzenes;
organic amino compound
tetraethylammonium
Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)		2.0710quaternary ammonium ion
ns 1643
1,3-bis(2-hydroxy-5-trifluoromethylphenyl)urea: an antiarrhythmic agent that activates HERG channels; structure in first source		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Electrocardiogram QT Prolonged
[description not available]		02.2510
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		02.2510
Arrhythmia
[description not available]		02.0810
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.0810